Searchable abstracts of presentations at key conferences in endocrinology

ea0006dp12 | Diabetes, metabolism and cardiovascular | SFE2003

NOW YOU SEE IT, NOW YOU DON'T: A VARIABLE PITUITARY MASS

Lee S , Battersby R , Romanowski C , Newell-Price J

A 44 year old woman presented in November 2000 with a two week history of headaches, vomiting and blurred vision. Past history consisted of type 2 diabetes and migraine. Initial investigation revealed hyponatraemia (sodium 114 mmol/l) and deranged liver biochemistry. ANA, anti dsDNA, cANCA, pANCA, anti Ro, La, RNP, Scl-70, Jo-1, smooth muscle and mitochondrial antibodies were negative. MRI revealed a 13x18x15mm pituitary mass elevating the optic chaism, without evidence of rec...

ea0002p100 | Thyroid | SFE2001

Low as opposed to fully suppressed serum TSH levels in ambulant subjects; frequently a pointer to thyroid autonomy

Chatterjee S , O'Malley B , Price D , Fielding A , Aitken R

In laboratories employing 'front-line' sensitive TSH measurement, it is generally accepted that fully suppressed TSH levels (3rd generation assays) alongside normal free thyroid hormone levels indicate subclinical hyperthyroidism. However, low but not suppressed levels are often labelled as non-thyroidal illness.We investigated 25 successive ambulant individuals, identified over an 18 month period as having low but not fully suppressed TSH levels (3rd ge...

ea0073pep13.8 | Presented ePosters 13: Pituitary and Neuroendocrinology | ECE2021

Use of antisense oligonucleotides as a therapy for Cushing’s disease

Kemp Elizabeth , Eltumi Hanan , Whatmore Jacob , John Newell-Price

BackgroundCushing’s disease (CD) is caused by high levels of blood cortisol resulting from excess secretion of adrenocorticotropic hormone (ACTH) from an anterior pituitary corticotroph adenoma. Clinical manifestations include diabetes, hypertension, osteoporosis, and depression. If untreated, CD has an increased mortality of five-fold owing to cardiovascular comorbidities, stroke or raised vulnerability to infection. Currently, transsphenoidal surg...

ea0094op5.1 | Adrenal and Cardiovascular | SFEBES2023

Nocturnal metyrapone administration for cortisol suppression in macs: tolerability and impact on metabolic outcomes

Berry Simon , Iqbal Ahmed , Newell-Price John , Debono Miguel

Background: Mild autonomous cortisol secretion (MACS) in patients with adrenal incidentalomas has been associated with elevated cortisol levels during the nocturnal period resulting in a disturbed cortisol rhythm. We hypothesised that administration of nocturnal metyrapone, an 11-beta-hydroxylase inhibitor, previously shown to restore cortisol rhythm in MACS patients, could reduce metabolic complications in this patient group.Met...

ea0104oc2 | Oral Communications | SFEIES24

The orphan G protein-coupled receptor 35 (GPR35) has an antiresorptive role in primary human osteoclasts

Price Maria L. , Wyatt Rachael A. , Frost Morten , Gorvin Caroline M.

The physiological role of the orphan G-protein coupled receptor 35 (GPR35) is currently unknown. Expression of the GPR35 gene and protein are downregulated in osteoporosis patients and in mouse models of the disease. Gpr35-knockout mice have reduced bone mass, while a synthetic GPR35 ligand, rescues bone loss in rodent osteoporosis models indicating that GPR35 has an important role in bone. Our previous studies demonstrated GPR35 is highly expressed in human ...

ea0077p252 | Thyroid | SFEBES2021

? Toxic nodule or Thyroid Carcinoma

Shaikh Ayesha , Saraf Asish , Udiawar Maneesh , Egan Richard , Price David , Boregowda Kusuma

Introduction: Risk of thyroid cancer is 17-32% in cold nodules and <1 % in hot nodules. Hot nodules are usually associated with Thyrotoxicosis. Patients with thyroid carcinoma are usually euthyroid but may be associated with hypothyroidism. We report 3 patients with hyperthyroidism and associated thyroid carcinoma.Case 1: A 17 years old lady presented with a lump in the neck and examination revealed prominent nodule on the right. TFTs were suggestive...

ea0081ep827 | Pituitary and Neuroendocrinology | ECE2022

Management of SIADH in patients with acute admissions to hospital: a single centre experience

Shah Vinit , Neale Francesca , Condurache Dorina , Baleswaran Saranya , Price Amy , Seetho Ian

Background: Hyponatraemia is a common electrolyte abnormality that is associated with significant morbidity and mortality in patients admitted to hospital. Fluid restriction is the recommended treatment option for syndrome of inappropriate antidiuretic hormone secretion (SIADH), a common cause of hyponatraemia with limited evidence for alternative treatment options. The aim of our study was to share the experience of our hospital in the successful management of SIADH where we ...

ea0050p275 | Neuroendocrinology and Pituitary | SFEBES2017

Long-term safety of gamma knife radiosurgery (STRS) for acromegaly

Rajapaksa Kaveesha , Sims-Williams Hugh P , Yianni John , Sinha Saurabh , Newell-Price John

Introduction: Incompletely controlled acromegaly has a three-fold excess all-cause mortality, with stroke being the predominant cause of death. Debate exists about the relationship between fractionated radiation (FRT) and risk of stroke, with radiation damage to cerebral vasculature potentially being a cause. We present outcomes in patients treated by gamma knife STRS at the National Centre for Stereotactic Radiosurgery in Sheffield, with...

ea0050p275 | Neuroendocrinology and Pituitary | SFEBES2017

Long-term safety of gamma knife radiosurgery (STRS) for acromegaly

Rajapaksa Kaveesha , Sims-Williams Hugh P , Yianni John , Sinha Saurabh , Newell-Price John

Introduction: Incompletely controlled acromegaly has a three-fold excess all-cause mortality, with stroke being the predominant cause of death. Debate exists about the relationship between fractionated radiation (FRT) and risk of stroke, with radiation damage to cerebral vasculature potentially being a cause. We present outcomes in patients treated by gamma knife STRS at the National Centre for Stereotactic Radiosurgery in Sheffield, with...

ea0085oc9.7 | Oral Communications 9 | BSPED2022

Liraglutide for the treatment of severe obesity in children: early experiences from a tier 3 paediatric weight management service

Hawton Katherine , Price-Drewett Olivia , Wenn Melanie , Fitzgerald Amy , Hamilton-Shield Julian , Giri Dinesh

Background: Liraglutide is a glucagon-like peptide analogue recently approved for use in children and young people for treating obesity. It is recommended for use within multidisciplinary weight management services, alongside dietetic and lifestyle interventions, in children over 12 years with severe obesity.Aim: To describe our experiences of using liraglutide in a tier 3 paediatric obesity service in a patient cohort who had previously failed to succes...